BioInvent and HGSI Announce Collaboration for Therapeutic Antibodies
News Mar 12, 2010
BioInvent International AB and Human Genome Sciences, Inc. have announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.
Under the terms of the agreement, BioInvent will apply its antibody discovery technology to generate and develop monoclonal antibody candidates.
The collaboration will initially focus on the development of antibodies in the field of inflammation. BioInvent and HGS will each have the right to participate in development and global commercialization of each antibody candidate, and will share research, development, manufacturing and commercialization costs as well as future revenues. Specific terms were not disclosed.
Svein Mathisen, Chief Executive Officer of BioInvent, said “Access to commercially attractive targets to which we can apply our antibody discovery engine is an important part of BioInvent’s strategy. We believe this collaborative agreement is a strong and valuable way of building our pipeline of innovative drugs as BioInvent and HGS’s research strengths are both complementary and synergistic. We are looking forward to working closely with HGS in what we believe will be a long-term, productive collaboration.”
“We continue to make excellent progress in advancing our late-stage products toward commercialization, and at the same time we remain committed to building and advancing our research pipeline to ensure sustainable growth well into the future,” said H. Thomas Watkins, President and Chief Executive Officer, HGS0.
He continued, “We look forward to collaborating with BioInvent to apply their proprietary technology to the development of targeted new therapies based on HGS discoveries.”
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE
Genetics Help Make a Weed a WeedNews
A study has has found that the success of weedy and invasive plants like the Jerusalem artichoke lies in their genes. Understanding how invasive plants evolve and the genes that enable them to thrive in a new environment is key to better understanding why they are wreaking havoc on natural landscapes and food production around the world.READ MORE